US Patent Issued to Nacuity Pharmaceuticals on June 30 for "Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide" (Texas Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,667,548, issued on June 30, was assigned to Nacuity Pharmaceuticals Inc. (Fort Worth, Texas).

"Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide" was invented by Jami Kern (Fort Worth, Texas) and G. Michael Wall (Fort Worth, Texas).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA)."

The patent was filed on Sept. 24, 2025, under Application No. 19/338,634.

*For further information, including images, ch...